



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

NOTICE OF ALLOWANCE AND ISSUE FEE DUE

MEGNER & DRETSCHWEIDER STE. 740, 1920 N STREET, N.W. WASHINGTON, DC 20036 All communications regarding this application should give the serial number, date of filing, name of applicant, and batch number.

Please direct all communications to the Attention of "OFFICE OF PUBLICATIONS" unless advised to the contrary.

The application identified below has been examined and found allowable

for issuance of Letters Patent, PROSECUTION ON THE MERITS IS CLOSED SC/SERIAL NO. FILING DATE TOTAL CLAIMS EXAMINER AND GROUP ART UNIT DATE MAILED 121 11/10/92 DENTZ: 3 06/313:601 107217810.12First Named Applicant . IT CON- PITERE RAPLAND

TITLE OF

IMIDAZO(1:2-A) PYRIDINE DERIVATIVES AND THEIR APPLICATION AS

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN, TYPE	SMALL ENTITY	FEE DUE	DATE DUE
HCW18524	424-256.000	N28	UTILITY	' RO	\$500.00	02/10/33

The amount of the issue fee is specified by 37 C.F.R. 1.18 as follows: for an original or reissue patent, except for a design or plant patent, \$500. If the epplicant qualifies for and has filed a verified statement of smell entity status in accordance with 37 C.F.R. 1.27, the issue fee is one-half the respective amount aforementioned. The issue fee due printed above reflects applicant's status as of the time of mailing this notice. A verified statement of small entity status may be filed prior to or with payment of the issue fee. However, in accordance with 37 C.F.R. 1.25, failure to establish status as a small entity or to or with payment of the issue fee precludes payment of the issue fee in the emount so esteblished for smell entities and precludes a refund of any portion thereof paid prior to establishing status as a small entity.

THE ISSUE FEE MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE as indicated above. The application shall otherwise be regarded as ABANDONDED. The issue fee will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the Patent and Trademark Office. Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of the notice of allowence, the issue fee is charged to the deposit account at the time of mailing of this notice in accordance with 37 C.F.R. 1.311. [If the issue fee has been so charged, it is indicated above,

In order to minimize delays in the issuance of a patent based on this application, this Notice may have been mailed prior to completion of final processing. The nature and/or extent of the remaining revision or processing requirements may cause slight delays of the patent. In addition, if prosecution is to be reopened, this Notice of Allowance will be veated and the appropriate Office action will follow in due course. If the issue fee has already been paid and prosecution is reopened, the applicant may request a refund or request that the fee be credited to a Deposit Account. However, applicant may wait until the application is either found allowable or held abandoned. If allowed, upon receipt of a new Notice of Allowance, applicant may request that the previously submitted issue fee be applied. If abandoned, epplicant may request refund or credit to a Deposit Account.

In the case of each patent issuing without an assignment, the complete post office address of the inventor(s) will be printed in the patent heading and in the Official Gazette. If the inventor's address is now different from the address which appears in the application, please fill in the information in the spaces provided on PTOL-85b enclosed. If there ere address changes for more than two inventors, enter the additional addresses on the reverse side of the PTOL-85b.

The appropriate spaces in the ASSIGMMENT DATA section of PTOL-85b must be completed in all cases. If it is desired to have the patent issue to an assigneen must have been previously submitted to the Patent and Trademark Officer must be submitted not later than the date of payment of the issue fee as required by 37 C.F.R. 1.334. Where there is an assignment, the assignee's name and address must be provided on the PTOL-95b to ensure its inclusion in the printed patent.

Advance orders for 10 or more printed copies of the prospective patent can be made by completing the information in Section 4 of PTOL-85b and submitting payment therewith. If use of a Deposit Account is being authorized for payment, PTOL-85c should also be frowarded. The order must be for at least 10 copies end must accompany the issue fee, The copies ordered will be sent only to the address specified in section 1 or 1 of PTOL-85b.

ΥJ	Note attached communication from Examiner.
\Box	This notice is issued in view of

IMPORTANT

ATTENTION IS DIRECTED TO 37 C.F.R. 1.334

THE PATENT WILL ISSUE TO APPLICANT UNLESS AN ASSIGNEE IS SHOWN IN ITEM 3 ON FORM PTO L-85b, ATTACHED



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

			· wasnington,	D.G. 20231
	SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
	313601	10/21/81	Jean-Pierre Kaplan	HCW18524

Wegner & Bretschneider Ste. 740, 1920 N Street N. W. Washington, DC 20036 Dentz

ART UNIT PAPER NUMBER

121

DATE MAILED: Washington

This is a communication from the examiner in charge of your application

COMMISSIONER OF PATENTS AND TRADEMARKS

COMMISSIONER OF FATERIS AND TRADEMARKS					
THIS IS AN ATTACHMENT TO THE NOTICE OF ALLOWANCE AND BASE ISSUE FEE DUE	· - (to ·	1. The second of			
ANOT the claims being allowable PROSECUTION ON THE MERITS IS CLOSED in this applica	tion in view of: (if not attac	hed hereto, a Notice.	of Allowance or o	ther	
\$ \$20/1663					
a. Applicant's communication filed		1 - 1	- 1		
b. Interview summarized on attached EXAMINER INTERVIEW SUMMARY RECORD.		18.7		1.	
c. Examiner's Amendment to the Record below. Should the changes and/or additions to may be proposed as provided by 37 C.F.R. 1.312. To ensure consideration of such	below be unacceptable to a n an amendment; it must b	pplicant, an appropri	ate amendment to or with the remitte	the record	
Base Issue Fee					
d. An Examiner's Amendment will follow.		15			
e The allowed claims are 2 and 9-18	-				
PROSECUTION ON THE MERITS REMAINS CLOSED. Should the changes and/or additions to	pelow be unacceptable to a	pplicant, an appropri	ate amendment to	the record	
may be proposed as provided 37 C.F.R. 1,312. To ensure consideration of such an amendment.	it must be submitted before	a or with the remittan	ce of the Base Iss	ue Fee.	
EXAMINER'S AMENDMENT TO THE	RECORD				
 Note statement of reasons for allowance contained below. Any comments considered necessation than the payment of the Base Issue Fee, preferably with it: to avoid processing delays. Such story Allowance." 	ry by applicant regarding r submissions should be clea	easons for allowance rly labeled "Comme	must be submittents on Statement	ed no later of Reasons	
Note attached NOTICE OF REFERENCES CITED, PTO - 892, which is part of this commun	ication. The listed reference	ces are considered to	be pertinent to t	he claimed	
invention, but the claims are deemed to be patentable thereover.				X.	
Note attached LIST OF PRIOR ART CITED BY APPLICANT, PTO-1449, which is part of this prior art statement. The references which were considered have been initialed on the form by the prior art statement. The references which were considered have been initialed on the form by the prior art statement.	communication and serve ne examiner, and the claims	s as an acknowledgn are deemed patenta	nent of receipt of ble-thereover.	applicant	
D. The formal drawings filed on are ac	cceptable				
The drawing correction request filed on	has been ap	proved	disapproved		
Acknowledgement is made of the claim for priority under 35 U.S.C. 119. The certified copy has	been received				
not been received.	rial no				
	filed on				
3. Dubte amendment to Specification, Claims and/or Drawing contained solew On ne	xt page.	500 mg	et in per		
	. •				

Serial No. 313601

Art Unit 121

2

In the title delete the phrase beginning with "Useful In Therapy" and ending with "Preparation".

In the title after "derivatives" insert -- And their Application as Pharmaceuticals --.

Claim 16, line 2, change "effective" to --effect-

2

Dentz:bjk

A/C 703

557-2517

10/18/82

enry R. in